The research report on the Alzheimer’s drugs market provides a comprehensive snapshot of the trends, growth drivers and restraints that will influence the market over the forecast period 2012 to 2018. The report analyzes these shifting dynamics to come up with accurate projections for the market in the coming years. Our analysts lay emphasis on factors such as: recent technological developments, competitive mapping, analysis using Porter’s five forces model, and company profiles for insight into the financial standing, product pipelines and new initiatives of players in the Alzheimer’s drugs market.
View Exclusive Global Strategic Business Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1245
This report also takes into account the macro and micro aspects of this market that will influence business-related decisions pertaining to Alzheimer’s drugs. It enumerates the factors that will prove essential for the sustenance and growth of enterprises in the global Alzheimer’s drugs market. Further, by studying the value chain and market structure in depth, the report gives businesses unmatched visibility into the opportunities that can be effectively monetized in the Alzheimer’s drugs market. By studying market projections for the years until 2018, this report is able to provide estimates that supplement prudent investments in the Alzheimer’s drugs market.
Alzheimer’s disease is classified as a progressive neurological disease that affects the functioning of the brain, ultimately leading to neuron loss. The combined effects of this neurological degradation are: the loss of reasoning abilities and memory.
Currently, the market offers no definitive treatment to prevent or cure Alzheimer’s disease – the only result currently offered by Alzheimer’s drugs is to curtail the progression of the disease. Patients of Alzheimer’s are usually prescribed neurotransmitters such as memantine and cholinesterase inhibitors. These drugs work by slowing down the progression of Alzheimer’s disease. They also provide temporary relief from common Alzheimer’s symptoms such as anxiety, depression, and insomnia, as well as agitation in some instances.
A method to provide early diagnosis of Alzheimer’s is not yet available – but there is a pressing demand on market players to offer techniques that enable the early detection of Alzheimer’s.
The estimates of this report show that the global Alzheimer’s drugs market will show sluggish growth over the forecast period. The growth will mainly slow down owing to a lack of techniques for diagnosing or treating Alzheimer’s disease.
Until now, the most dominant geographical region in the Alzheimer’s drugs market was North America, as it occupied 50% of market shares. While it will continue to hold its leading position, it will be overtaken – in terms of growth rate – by emerging economies such as Russia, India, China, and Australia as these regions experience high unmet medical needs.
The growing geriatric population is yet another reason that will impel growth in the global Alzheimer’s drugs market, making it imperative for players to launch new drugs and treatments. Many market players are now focusing on research and development centric activities, which could potentially result in breakthroughs. At the same time, the global Alzheimer’s drugs market will have to contend with challenges such as drug patent expiry.
Leading market participants that have been profiled in the Alzheimer’s drugs market research report are: Pfizer Incorporated, Forest Laboratories, Inc., Eisai Co., Ltd., Novartis AG, and H. Lundbeck A/S.
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453